Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

NCT03535363 PHASE1 COMPLETED

Investigating potential of controlling brain metastases in patients with EGFR positive NSCLC.

Details

Lead sponsor	Case Comprehensive Cancer Center
Phase	PHASE1
Status	COMPLETED
Enrolment	6
Start date	Fri Oct 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Apr 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• NSCLC
• Non-small Cell Lung Cancer

Interventions

• Osimertinib

Countries

United States